Infecciones invasivas debidas a Saprochaete capitata en pacientes con neoplasias hematológicas: informe de cinco casos y revisión del tratamiento antimicótico / Invasive infections caused by Saprochaete capitata in patients with haematological malignancies: report of five cases and review of the antifungal therapy

Background. Saprochaete capitata (formerly known as Geotrichum capitatum and Blastoschizomyces capitatus) is a ubiquitous fungus found in soil, water, air, plants and dairy products. It colonizes the skin, and bronchial and intestinal tract of healthy people producing serious opportunistic infections in patients with haematological malignancies, especially in those with acute leukaemia. Since 1960s its presence is being increasingly recognized in this group of patients. The clinical spectrum of S. capitata disseminated infections is very similar to that produced by Candida, being easily misinterpreted. The associated high mortality and low susceptibility to fluconazole and echinocandins of S. capitata require the acknowledgement of this emergent infection so that it can be properly treated. Case report. We report 5 new cases of S. capitata disseminated infection in patients with advanced haematological malignancies observed in the haematology unit between the years 2004 and 2010, and review the state-of-the-art for diagnosis and treatment of this infection. Conclusions. Based on our experience, the prophylactic use of or the empirical antifungal treatment with fluconazole and/or echinocandins would not be adequate for oncohaematological patients in those hospitals where S. capitata infection may be highly prevalent (AU)

Potential of anti-Candida antibodies in immunoprophylaxis.

The need for new options for the treatment of invasive candidiasis has fuelled the use of antibodies in combination with conventional antifungal therapy. After a long period of time in which antibodies were considered irrelevant in the resistance against invasive candidiasis, it was demonstrated that a number of antibodies or their engineered derivatives directed against Candida albicans cell-wall polysaccharides and glycopeptides, as well as against some protein epitopes, confer protection against invasive candidiasis. This has confirmed this approach as a new strategy for the prophylaxis of invasive candidiasis. Of particular interest is Mycograb, a human recombinant monoclonal antibody that inhibits heat shock protein 90, and has been administrated in combination with lipid-associated amphotericin B to patients with invasive candidiasis, and the fungicidal anti-beta-glucan antibodies induced by the glycoconjugate vaccine composed of a beta-glucan polysaccharide conjugated with the diphtheria toxoid CRM 197. However, despite the promising data obtained in vitro and in animal models, at present there is very little clinical experience on the use of antibodies in Candida immunoprophylaxis.

Procedimientos de diagnóstico microbiológico de las micosis y estudios de sensibilidad a los antifúngicos / Microbiological procedures for diagnosing mycoses and for antifungal susceptibility testing

Las infecciones fúngicas constituyen un problema diagnóstico y terapéutico de interés creciente debido, ante todo, al incremento y gravedad de las infecciones diseminadas en pacientes inmunodeprimidos. Los métodos diagnósticos basados en el cultivo son lentos y con sensibilidad insuficiente, por lo que se están desarrollando métodos diagnósticos basados en la detección de componentes genéticos, antigénicos o metabólicos específicos de los hongos, que permiten un diagnóstico y un tratamiento dirigido precoces. Por otra parte, se han estandarizado métodos para el estudio de la sensibilidad de los hongos a los antifúngicos, reproducibles y adaptables a un laboratorio asistencial, que permiten la detección de resistencias in vitro que se correlacionan con peor evolución clínica. En este trabajo revisamos los principales procedimientos microbiológicos para el diagnóstico de las infecciones causadas por hongos y los métodos desarrollados para los estudios de sensibilidad a los antifúngicos (AU)

Fungal infections are a diagnostic and therapeutic problem of increasing concern due to the frequency and severity of disseminated infection in immunocompromised patients. Culture-based methods are characteristically slow and have poor sensitivity; hence, other methods, based on the detection of fungus-specific genetic, antigenic and metabolic components are being developed to enable early diagnosis and specific treatment. Moreover, reproducible antifungal susceptibility methods that can be adapted for use in clinical laboratories have been standardized to allow in vitro detection of resistance, which correlates with a less favorable clinical outcome. In this paper we review the main microbiological procedures available for the diagnosis of fungal infections and for antifungal susceptibility testing (AU)